Hypothesis

Quercetin phytosome administered during the hepatic CYP3A4 activity nadir (approximately ZT14‑ZT18 in humans, i.e., early subjective night) generates higher peak aglycone exposure, stronger SIRT1‑dependent BMAL1 acetylation, and superior senescent cell clearance compared with dosing at the enzyme peak (ZT2‑ZT6).

Rationale

It's known that quercetin is a substrate and inhibitor of CYP3A4 and UGT enzymes that exhibit robust circadian oscillations in human liver[2][3]. When CYP3A4 activity's low, less quercetin undergoes oxidative metabolism, preserving more parent compound for cellular uptake and subsequent deglycosylation via phytosome‑mediated transport[1]. Concurrently, quercetin directly modulates core clock components—BMAL1, CLOCK, CRY1/2—and upregulates SIRT1 in peripheral tissues[4][5]. SIRT1 activity is NAD⁺‑dependent and itself clock‑controlled, creating a feedback loop where heightened SIRT1 amplifies BMAL1 transcriptional activity and drives expression of senolytic effectors such as FOXO3 and p53‑mediated apoptosis[4][5]. Dosing quercetin when CYP3A4 is trough therefore maximizes intracellular aglycone availability precisely when the SIRT1‑BMAL1 axis is primed for nocturnal reinforcement, leading to amplified p53‑FOXO3 signaling and increased clearance of SASP‑positive cells.

Predictions

1. Plasma quercetin aglycone Cmax and AUC₀‑∞ will be 1.5‑2‑fold higher after nighttime versus morning phytosome dosing in a crossover PK study.
2. Hepatic SIRT1 activity (measured by deacetylation of PGC‑1α) and BMAL1 acetylation status will show a synergistic increase only after nighttime dosing.
3. Ex vivo senolytic assays using human lung fibroblasts will reveal ≥30 % greater reduction in SA‑β‑gal‑positive cells following nighttime pretreatment.
4. In a small‑proof‑of‑concept trial, nighttime dosing will lower circulating SASP cytokines (IL‑6, IL‑8) more effectively than morning dosing after two weeks of intermittent administration.

Experimental Design

• Participants: 12 healthy volunteers (ages 30‑50) screened for normal liver function.
• Design: Randomized, double‑blind, crossover with two periods (night vs morning) separated by a 2‑week washout.
• Intervention: 300 mg quercetin phytosome (equivalent to 250 mg aglycone) administered at 02:00 h (night) or 10:00 h (morning) after an overnight fast.
• Sampling: Serial blood draws over 24 h for quercetin aglycone and metabolites (LC‑MS/MS), CYP3A4 activity marker (midazolam 1′‑hydroxy metabolite), UGT activity (bilirubin glucuronide), NAD⁺/NADH ratio, SIRT1 activity, and BMAL1 acetylation (immunoprecipitation from isolated PBMCs).
• Endpoints: Primary PK (Cmax, AUC₀‑∞); secondary pharmacodynamic (SIRT1 activity, BMAL1 acetylation, NAD⁺ levels); exploratory senolytic (plasma SASP cytokines, ex vivo fibroblast SA‑β‑gal reduction after plasma exposure).
• Statistical: Paired t‑test or Wilcoxon for PK/PD; ANOVA for cytokine changes; significance set at p<0.05.

If nighttime dosing consistently yields higher aglycone exposure coupled with amplified SIRT1‑BMAL1 signaling and superior senescent cell clearance, the hypothesis will be supported. Conversely, absence of a circadian PK/PD split would refute the notion that timing quercetin phytosome dosing to hepatic CYP3A4 trough confers added senolytic advantage.